In a major public health development, the Drug Regulatory Authority of Pakistan (DRAP) has taken decisive action by declaring ten commonly used medicines as substandard and imposing an immediate ban on their specific batches across Punjab. This crackdown comes after rigorous testing at the Drug Testing Laboratory revealed alarming quality issues, highlighting ongoing challenges in ensuring drug safety in Pakistan.
Substandard medicines in Punjab pose serious risks, including treatment failure, worsened health conditions, and potential hospitalization for vulnerable patients.
Substandard Medicines In Punjab
The affected medicines cover a wide range of essential treatments, from everyday ailments to critical conditions. Among them is “Daisy,” a popular tablet widely used for managing allergies, which failed quality standards and was deemed unsafe for consumption.
Similarly, “Escod,” a medication prescribed to reduce the risk of heart attacks and manage cardiovascular issues, was found to be substandard, raising concerns about its effectiveness and safety for heart patients relying on it daily.
Skin infection treatments have also been impacted, with “Canadex” – a commonly dispensed drug for bacterial skin conditions – now prohibited in specific batches due to poor quality findings. For those suffering from common colds and respiratory discomfort, “Cepizine” and “Rozan” have been flagged and banned, potentially disrupting access to relief for seasonal illnesses.
Eye care has not been spared, as “Nefen” eye drops, frequently used for infections and inflammation, were declared substandard following lab analysis.
Additionally, an injection commonly administered for varicose veins affecting the hands and feet has been included in the list of defective products, underscoring the breadth of this issue across different therapeutic categories.
These substandard medicines in Punjab were primarily manufactured by pharmaceutical companies located in Karachi’s Site Area and Manghopir industrial zones, as well as Lahore’s Sundar Industrial Area and Raiwind Road facilities. The involvement of production sites in major industrial hubs points to the need for stricter oversight in manufacturing processes to prevent such lapses.
DRAP’s swift response emphasizes patient safety as a top priority. The authority has explicitly prohibited the sale, distribution, and use of the identified batches nationwide, with instructions for pharmacies, hospitals, and healthcare providers to immediately stop dispensing them and initiate recalls where necessary.
Manufacturers are required to provide detailed distribution records and cooperate fully with regulatory teams to remove these products from the market.
This incident serves as a stark reminder of the critical importance of quality control in the pharmaceutical industry. Substandard medicines not only undermine treatment outcomes but can also erode public trust in healthcare systems.
Consumers in Punjab and across Pakistan are strongly advised to check batch numbers and consult pharmacists or doctors before using any of the mentioned drugs. Staying informed about DRAP alerts is essential for avoiding potential health hazards from compromised medications.
Ongoing investigations and further actions by DRAP aim to hold responsible parties accountable and strengthen enforcement mechanisms. As regulatory bodies continue monitoring, the public should remain vigilant and report any suspicious or recalled products to local authorities.
Prioritizing verified, high-quality medicines remains key to safeguarding health in the face of such challenges. For the latest updates on substandard medicines in Punjab, refer to official DRAP notifications and advisories.
